Quarterly report pursuant to sections 13 or 15(d)

Note 5 - Stockholders' Equity

v2.4.0.8
Note 5 - Stockholders' Equity
6 Months Ended
Jun. 30, 2013
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]

5.  

Stockholders’ Equity  


January 2013 Private Placement


In January 2013, the Company entered into a securities purchase agreement for the private placement of shares of the Company’s common stock and warrants to purchase shares of the Company’s common stock, at a purchase price of $1.20 per unit (the “January 2013 Financing Transaction”). Each unit consisted of one share of common stock and a warrant to purchase one-half share of common stock.


In the January 2013 Financing Transaction, the Company sold to the investors 9,201,684 shares of common stock, together with warrants to purchase 4,600,842 shares of common stock, for aggregate gross proceeds of $11,042,021, before commissions and offering expenses. Non-employee directors of the Company invested a total of $402,000 in the January 2013 Financing Transaction. Each warrant is exercisable for five years from the date of issuance and has an exercise price of $1.75 per share, subject to adjustment from time to time for stock splits or combinations, stock dividends, stock distributions, recapitalizations and other similar transactions. In the event the Company issues shares of its common stock or common stock equivalents in a subsequent financing transaction at a price below the then prevailing warrant exercise price, the exercise price of the warrants will be adjusted downward (commonly referred to as a “down round” provision) to the price at which the Company issues the common stock or common stock equivalents.


In addition, the warrants contain a net-cash settlement feature which gives the warrant holder the right to net-cash settlement in the event certain transactions occur. Pursuant to the net-cash settlement provision of the warrants, if such a transaction occurs, the warrant holder will be entitled to receive cash equal to the value calculated under the Black-Scholes valuation model using (i) an expected volatility equal to the greater of 100% and the 100-day volatility obtained from the HVT function on Bloomberg, (ii) an expected term equal to the remaining term of the warrant, and (iii) an interest rate equal to the United States Treasury risk-free rate for the term of the lesser of the remaining term of the warrant or twenty-four months.


The Company’s placement agents earned commissions of $1,104,202 and the Company incurred other transaction costs of $133,024 related to the January Financing Transaction.


In connection with the January Financing Transaction, the Company entered into a registration rights agreement with the investors pursuant to which the Company filed a registration statement with the SEC covering the resale of the shares of common stock and the shares of common stock underlying the warrants issued in the financing. The Company must bear the costs, including legal and accounting fees, associated with the registration of those shares. If the Company fails to continuously maintain the effectiveness of the registration statement (with certain permitted exceptions), the Company will incur certain damages to the investors, up to a maximum amount of 12% of the investors’ investments in the January Financing Transaction, or approximately $1,300,000.


Common Stock Warrants Requiring Liability Accounting


Under guidance in ASC 815-40, “Contracts in Entity's Own Equity,” the net-cash settlement and down round provisions contained in the warrants issued in the January 2013 Financing Transaction require derivative liability accounting treatment for thee warrants. Likewise, under ASC 815-40, the down round provision contained in the warrants issued in the July 2012 Financing Transaction also require derivative liability accounting treatment for the warrants. As of June 30, 2013 and December 31, 2012, the aggregate fair value of these warrants was $2,855,367 and $2,128,302, respectively. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method.


Assumptions used in calculating the fair value of these warrants were as noted below (including assumptions used in calculating the transaction date fair value for the warrants issued in the January 2013 Financing Transaction):


   

January 2013

Financing

Transaction

Date

   

June 30,

2013

 

Dividend yield

    0%         0%    

Expected volatility

  47.08% - 100.00%     46.54% - 100.00%  

Risk free interest rate

    0.91%       1.05% - 1.27%  

Expected remaining term (in years)

    5       4.01 to 4.57  

In addition to the assumptions above, the Company also takes into consideration whether or not the Company would participate in another round of equity financing and, if so, what that stock price would be for such a financing at that time.


The change in the fair value of the warrants accounted for as derivative liabilities is reflected below:


Balance at January 1, 2013 

  $ 2,128,302  

Fair value of warrants issued in January

       

Financing Transaction at transaction date

    3,305,245  

Decrease in fair value resulting in gain

    (2,578,180 )

Fair value at June 30, 2013

  $ 2,855,367  

The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants.


Stock Options


In June 2013, the stockholders of the Company approved the creation of a new share-based incentive plan (the “2013 Plan”). Following stockholder approval of the 2013 Plan, no new grants under the Company’s prior stock plans were made. A total of 1,250,000 shares of the Company’s common stock are reserved for issuance under the 2013 Plan, of which awards as to 277,500 shares had been made as of June 30, 2013. Thus, 972,500 shares remained available for award grants as of June 30, 2013 under the 2013 Plan.


Activity under all of the Company’s equity compensation plans during the six months ended June 30, 2013 is summarized below:


Shares

Weighted -

Average

Exercise

Price

Outstanding at January 1, 2013 

6,432,127 $ 1.58

Granted 

347,500 1.14

Forfeited 

(25,000 ) 2.09

Outstanding at June 30, 2013 

6,754,627 1.55

The estimated grant date fair values of options granted during the six months ended June 30, 2013 were calculated using the Black-Scholes valuation model, based on the following assumptions:


Dividend yield 

0%

Expected Volatility 

45.33% to 45.96%

Risk free Interest rates 

0.92% to 1.38%

Expected lives (years) 

5.5

to  

6.0

The Company records share-based compensation expense on a straight-line basis over the related vesting period. For the periods indicated below, employee share-based compensation expense related to options was:


 

Three Months Ended June 30,

   

Six Months Ended June 30,

 
 

2013

   

2012

   

2013

   

2012

 
  $ 324,124     $ 313,707     $ 642,591     $ 543,562  

        As of June 30, 2013, there was unrecognized compensation expense of $1,429,490 related to outstanding stock options which is expected to be recognized over a weighted average period of approximately 1.5 years.

Warrants


Warrants have generally been issued for terms of up to five years. Common stock warrant activity for the six months ended June 30, 2013 is as follows:


   

Shares

   

Weighted -

Average

Exercise

Price

 

Outstanding at January 1, 2013 

    8,763,836     $ 0.95  

Issued 

    4,600,842       1.75  

Forfeited 

    (41,666 )     1.00  

Exercised 

    (463,500 )     0.13  

Outstanding at June 30, 2013 

    12,859,512       1.27  

During the six months ended June 30, 2013, certain warrants were exercised on a net settlement basis which resulted in the Company withholding 25,237 shares out of the common stock warrants exercised.